Ultrasound Guided Combined Adductor Canal, Superior Genicular Nerves and Anterior Femoral Cutaneous Nerves Blocks in Comparison With Periarticular Local Anesthesia Infiltration in Primary Total Knee Arthroplasty
Analgesic Efficacy of Ultrasound Guided Combined Adductor Canal, Superior Genicular Nerves and Anterior Femoral Cutaneous Nerves Blocks in Comparison With Periarticular Local Anesthesia Infiltration in Primary Total Knee Arthroplasty: A Prospective Randomized Trial
1 other identifier
interventional
64
1 country
1
Brief Summary
Background: Pain management in total knee arthroplasty continues to evolve especially as an early postoperative analgesia is of paramount importance in achieving patient satisfaction and improving clinical outcomes. The goal of achieving an ideal analgesia modality which facilitates early rehabilitation, prevents knee stiffness, reduces hospital stay due to pain, and promotes good functional outcomes continues to be elusive. Multimodal analgesia has been devised to control postoperative pain and reduce opioid consumption including periarticular injection and peripheral nerve blocks. Rationale: Assess the efficacy of a triple block including Adductor canal block, superior lateral, superior medial genicular nerves block and anterior femoral cutaneous nerves block in comparison with Periarticular infiltration for pain management in patients undergoing a total knee arthroplasty. Methods: Prospective Randomized Control Trial
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
CompletedFirst Submitted
Initial submission to the registry
July 5, 2026
CompletedFirst Posted
Study publicly available on registry
July 15, 2026
CompletedJuly 15, 2026
July 1, 2026
1.2 years
July 5, 2026
July 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
End of Analgesia Time
Time from the end of surgery until the first Numeric Rating Scale (NRS) pain score ≥ 4.
Within the first 24 hours after surgery.
Secondary Outcomes (6)
Total Morphine Consumption (mg)
During the first 24 hours after surgery
Total Tramadol Consumption (mg)
During the first 24 hours after discharge
Heart rate (Beat/minute)
During the first 24 hours after surgery
Blood pressure (mmHg)
During the first 24 hours after surgery
Patient Satisfaction Score
At 24 hours after surgery
- +1 more secondary outcomes
Study Arms (2)
Periarticular Infiltration Analgesia Group
ACTIVE COMPARATORIt will be infiltrated by the surgeon before prosthesis implantation.
Triple Block Group
ACTIVE COMPARATORPatients will receive ultrasound-guided adductor canal, infrapatellar, medial cutaneous, and superior genicular nerve blocks.
Interventions
A total volume of 60 mL containing bupivacaine, ketorolac, adrenaline, and tranexamic acid will be infiltrated by the surgeon before prosthesis implantation into the posterior capsule, medial and lateral gutters, quadriceps mechanism, patellar tendon, and medial periosteum.
Patients will receive a mixture of 45 mL of 0.25% bupivacaine and 8 mg dexamethasone. A total of 15 mL will be injected into the adductor canal, 10 mL for the infrapatellar and medial cutaneous nerve blocks, and 10 mL each for the superior medial and superior lateral genicular nerve blocks.
Eligibility Criteria
You may qualify if:
- ASA: I \& II
- Gender: Male \& Female
- Age: 18and above
- BMI less than 40 kg/m2
- Patients are scheduled for primary unilateral total knee arthroplasty.
You may not qualify if:
- Patients with contraindications to spinal anesthesia
- Failed spinal anesthesia.
- ASA III-IV
- Body mass index (BMI)≥40,
- A known allergy or contraindication to the drugs used in this study.
- Previous knee surgery.
- Renal impairment.
- Patients who suffer from chronic neuropathic pain or on regular pain medications other than NSAIDs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- SAMEH ELSHERBINIlead
Study Sites (1)
Qassim University Medical City
Buraidah, Al-Qassim Region, Saudi Arabia
Study Officials
- PRINCIPAL INVESTIGATOR
OMAR S Almisnid, Anesthesia Consultant
Department of Anesthesia, College of Medicine, Qassim University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Associate Professor of Anesthesia
Study Record Dates
First Submitted
July 5, 2026
First Posted
July 15, 2026
Study Start
January 1, 2025
Primary Completion
April 1, 2026
Study Completion
July 1, 2026
Last Updated
July 15, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share